{"title":"人类免疫缺陷病毒-1潜伏期的调控及其再激活。","authors":"E Verdin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Treatment of human immunodeficiency virus (HIV) infection with highly active antiretroviral therapy (HAART) has become highly effective. However the persistence of a small population of infected cells containing transcriptionally silent but re-activatable HIV proviruses prevents complete elimination of the infection. Here, we review recent progress in our understanding of the molecular mechanisms underlying HIV proviral latency and highlight experimental therapies designed to eliminate the latent population.</p>","PeriodicalId":75641,"journal":{"name":"Bulletin et memoires de l'Academie royale de medecine de Belgique","volume":"163 6","pages":"355-64; discussion 364-5"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regulation of human immunodeficiency virus-1 latency and its reactivation.\",\"authors\":\"E Verdin\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Treatment of human immunodeficiency virus (HIV) infection with highly active antiretroviral therapy (HAART) has become highly effective. However the persistence of a small population of infected cells containing transcriptionally silent but re-activatable HIV proviruses prevents complete elimination of the infection. Here, we review recent progress in our understanding of the molecular mechanisms underlying HIV proviral latency and highlight experimental therapies designed to eliminate the latent population.</p>\",\"PeriodicalId\":75641,\"journal\":{\"name\":\"Bulletin et memoires de l'Academie royale de medecine de Belgique\",\"volume\":\"163 6\",\"pages\":\"355-64; discussion 364-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin et memoires de l'Academie royale de medecine de Belgique\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin et memoires de l'Academie royale de medecine de Belgique","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Regulation of human immunodeficiency virus-1 latency and its reactivation.
Treatment of human immunodeficiency virus (HIV) infection with highly active antiretroviral therapy (HAART) has become highly effective. However the persistence of a small population of infected cells containing transcriptionally silent but re-activatable HIV proviruses prevents complete elimination of the infection. Here, we review recent progress in our understanding of the molecular mechanisms underlying HIV proviral latency and highlight experimental therapies designed to eliminate the latent population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
